-
子宫内膜癌(EC)在肿瘤科、妇产科中属常见、多发的女性生殖系统恶性肿瘤之一,多发群体以围绝经期、绝经后女性居多。主要是指发生在子宫内膜的上皮肿瘤,该病的发生、发展与病人的生活方式密切相关[1],致死率仅次于卵巢癌和宫颈癌(主要针对女性人群),年新发病例约20万左右,有显著的地域性特征[2]。人附睾分泌蛋白4(HE4)是一种新型肿瘤标志物,在癌发生、发展过程中表达水平升高[3]。糖类抗原125(CA125)是常见糖蛋白之一,主要来源于体腔上皮细胞,在正常组织中表达量较低,但当机体受损时则会随之升高[4],因此应对女性卵巢癌病人提供CA125血液检测[5]。近年来,越来越多的临床案例表明,HE4和CA125表达水平在子宫内膜癌中均有所上升,但将其作为子宫内膜癌的肿瘤标志物是否合适仍有待更深层次的研究证实。本文就HE4和CA125表达水平结合超声在子宫内膜癌诊断中的诊断价值作一探讨。
-
恶性组阴道彩色多普勒超声检查78例存在异常。超声表现:以子宫体积增大和子宫内膜增厚为主,边缘不规则。子宫最大径(68.95±8.75)mm,子宫内膜平均厚度(36.71±9.35)mm;病灶回声:7例子宫内膜病灶不均匀低回声,26例低回声晕中断,15例回声消失;血流情况:5例无血流信号,23例有点条状血流信号,10例有网状血流信号;病灶浸润深度:7例无浸润,35例浸润子宫浅肌层,22例浸润子宫深肌层。
-
恶性组HE4、CA125表达水平高于良性组、对照组,良性组高于对照组(P<0.05)(见表 1)。
分组 n HE4/(pmol/L) CA125/(kU/L) 恶性组 101 254.23±30.75 51.23±7.53 良性组 103 185.64±16.75* 41.31±5.87* 对照组 105 122.31±15.34*# 32.45±6.12*# F — 902.51 207.95 P — < 0.01 < 0.01 MS组内 — 487.147 42.871 q检验:与恶性组比较*P<0.05;与良性组比较#P<0.05 表 1 3组血清HE4、CA125表达水平比较(x±s)
-
恶性组血清HE4、CA125阳性率均高于良性组、对照组,良性组高于对照组(P<0.05)(见表 2)。
分组 n HE4 CA125 恶性组 101 78(77.23) 67(66.34) 良性组 103 36(34.95)# 32(31.07)* 对照组 105 1(0.95)*# 2(1.90)*# χ2 — 128.52 97.32 P — < 0.01 < 0.01 与恶性组比较*P<0.05;与良性组比较#P<0.05 表 2 3组血清HE4、CA125阳性率比较[n;百分率(%)]
-
联合诊断的敏感度、诊断比值比均高于单独的HE4、CA125及超声诊断(P<0.01和P < 0.05),而特异度差异无统计学意义(P>0.05)(见表 3)。单纯的HE4、CA125及超声诊断在最佳诊断点时的AUC值分别为0.725、0.713、0.723,三者联合诊断时的AUC值为0.867。
检测项目 敏感度 特异度 诊断比值比 HE4 61.23 90.57 78.52 CA125 67.63 91.50 76.34 超声 78.54 91.24 83.66 HE4+CA125+超声 93.67 95.61 96.75 χ2 15.34 1.79 9.70 P < 0.01 >0.05 < 0.05 表 3 HE4、CA125及超声单独及联合检测在子宫内膜癌诊断中的评价(ni=101;%)
人附睾分泌蛋白4、糖链多肽抗原125联合超声对绝经后子宫内膜癌的诊断价值
Prediction and diagnosis of postmenopausal endometrial cancer by the combination of human epididymal secretory protein 4, carbohydrate antigen 125 and ultrasound
-
摘要:
目的探讨人附睾分泌蛋白4(HE4)、糖链多肽抗原125(CA125)联合超声对绝经后子宫内膜癌的诊断价值。 方法选取绝经后子宫内膜癌病人101例(恶性组),绝经后子宫内膜增生病人103例(良性组),同时期来院健康体检的绝经健康女性105名(对照组),分别检测3组受试者的HE4、CA125水平,分别计算其合并状态时的敏感度、特异度及诊断比值比,并计算受试者工作特征曲线下面积(AUC)值。 结果恶性组阴道彩色多普勒超声检查78例存在异常。恶性组HE4、CA125表达水平及阳性率均高于良性组、对照组,良性组高于对照组(P < 0.05)。联合诊断的敏感度、诊断比值比均高于单独的HE4、CA125及超声诊断(P < 0.01和P < 0.05),而特异度差异无统计学意义(P>0.05)。单纯的HE4、CA125及超声诊断在最佳诊断点时的AUC值分别为0.725、0.713、0.723,三者联合诊断时的AUC值为0.867。 结论采用HE4、CA125联合超声诊断较单独诊断子宫内膜癌时整体效能更佳,临床应用与推广价值较好。 Abstract:ObjectiveTo investigate the diagnostic value of human epididymal secretory protein 4 (HE4), carbohydrate antigen 125 (CA125) combined with ultrasound in postmenopausal endometrial carcinoma. MethodsA total of 101 patients with postmenopausal endometrial cancer were selected as malignant group, 103 patients with postmenopausal endometrial hyperplasia as benign group, and 105 menopausal healthy examinees as control group.The levels of HE4 and CA125 in three groups were detected.The sensitivity, specificity and diagnostic odds ratio were calculated under combined detection, and the area under the receiver operating characteristic curve (AUC) was calculated. ResultsSeventy-eight abnormal cases were found in malignant group by colorful Doppler ultrasound.The expression level and positive rate of HE4 and CA125 in malignant group were higher than those in benign group and control group, and which in benign group were higher than those in control group(P < 0.05 to P < 0.01).The sensitivity and diagnostic odds ratio of combined diagnosis were higher than that of HE4, CA125 and ultrasound alone(P < 0.01 and P < 0.05), but the specificity between them was not statistically significant(P>0.05).The AUC values of simple HE4, CA125 and ultrasound diagnosis at the best diagnosis point were 0.725, 0.713 and 0.723, respectively, and the AUC value of combined diagnosis of HE4, CA125 and ultrasound was 0.867. ConclusionsCompared with simple diagnosis, the overall diagnostic efficacy of HE4 and CA125 combined with ultrasound for endometrial tumor is better, which has better clinical application and promotion value. -
表 1 3组血清HE4、CA125表达水平比较(x±s)
分组 n HE4/(pmol/L) CA125/(kU/L) 恶性组 101 254.23±30.75 51.23±7.53 良性组 103 185.64±16.75* 41.31±5.87* 对照组 105 122.31±15.34*# 32.45±6.12*# F — 902.51 207.95 P — < 0.01 < 0.01 MS组内 — 487.147 42.871 q检验:与恶性组比较*P<0.05;与良性组比较#P<0.05 表 2 3组血清HE4、CA125阳性率比较[n;百分率(%)]
分组 n HE4 CA125 恶性组 101 78(77.23) 67(66.34) 良性组 103 36(34.95)# 32(31.07)* 对照组 105 1(0.95)*# 2(1.90)*# χ2 — 128.52 97.32 P — < 0.01 < 0.01 与恶性组比较*P<0.05;与良性组比较#P<0.05 表 3 HE4、CA125及超声单独及联合检测在子宫内膜癌诊断中的评价(ni=101;%)
检测项目 敏感度 特异度 诊断比值比 HE4 61.23 90.57 78.52 CA125 67.63 91.50 76.34 超声 78.54 91.24 83.66 HE4+CA125+超声 93.67 95.61 96.75 χ2 15.34 1.79 9.70 P < 0.01 >0.05 < 0.05 -
[1] 汤希炜, 易婷, 刘丹.血清人附睾蛋白4联合癌抗原125诊断子宫内膜癌的临床价值探析[J].当代医学, 2019, 25(25):1. [2] 寇建芳, 孟跃进.宫腔镜检查联合血清人附睾分泌蛋白及糖类抗原和miR-21早期诊断子宫内膜癌的临床价值[J].新乡医学院学报, 2019, 36(2):90. [3] 胡玲莉, 郭万华, 陈德柱.人附睾蛋白4和糖类抗原125对子宫内膜癌早期诊断价值的系统评价[J].中国循证医学杂志, 2015, 15(9):1049. [4] CHUNHUA D, PING L, CHAO L.Value of HE4 combined with cancer Antigen 125in the diagnosis of Endometrial Cancer[J].Pak J Med Sci, 2017, 33(4):1013. [5] DINIZ G, KARADENIZ T, SAYHAN S, et al.Tissue expression of human epididymal secretory protein 4 may be useful in the differential diagnosis of uterine cervical tumors[J].Ginekol Pol, 2017, 88(2):51. doi: 10.5603/GP.a2017.0011 [6] 周琦, 吴小华, 刘继红.子宫内膜癌诊断与治疗指南(第四版)[J].中国实用妇科与产科杂志, 2018, 34(8):52. [7] 黄奕.子宫内膜癌的综合治疗-2013NCCN指南解读[C].武汉: 湖北省抗癌协会会议论文集, 2013. [8] 周坚红, 丁志明, 张志华.妇产科常见疾病诊治指南, 中篇[M].杭州:浙江大学出版社, 2012. [9] 李小亚, 高炯, 谢洋, 等.子宫内膜癌病人经阴道彩色多普勒超声声像图特征及联合检测血浆糖类抗原125、糖类抗原19-9在辅助诊断中的价值[J].实用临床医药杂志, 2017, 21(13):219. [10] HOCK TB, LEONG Y S, WEE SW, et al.Evaluation in the predictive value of serum human epididymal protein 4(HE4), cancer antigen 125(CA125) and a combination of both in detecting ovarian malignancy[J].Horm Mol Biol Clin Investig, 2018, 35(1):29. [11] 严浩, 黄奕, 杨润峰, 等.血清人附睾分泌蛋白4和CA125联合检测对子宫内膜癌诊断的临床价值[J].中国妇幼保健, 2015, 30(34):5999. [12] 白朝怡, 王颖梅, 滕飞.血清人附睾分泌蛋白4及CA125联合检测对子宫内膜癌淋巴结转移的预测价值[J].中华妇产科杂志, 2014, 49(7):543. [13] 张爱敏, 张鹏.血清人附睾分泌蛋白E4和CA125联合检测对子宫内膜诊断的临床价值[J].中华妇产科杂志, 2012, 47(2):125. [14] 朱春霞, 孟勇, 王秀虹.血清人附睾分泌蛋白4、糖类抗原125和脂联素在子宫内膜癌淋巴结转移诊断中的价值[J].新乡医学院学报, 2016, 33(5):60. [15] 张爱敏, 张鹏.血清人附睾分泌蛋白4和CA125联合检测对子宫内膜癌诊断的临床价值[J].中华妇产科杂志, 2012, 47(2):125. [16] JING L, QU PP.The clinical value of human epididymis secretory protein 4, carbohydrate antigen 125 combined with risk of ovarian malignancy algorithm in the prediction and diagnosis of epithelial ovarian cancer[J].Chin J Pract Gynecol Obst, 2015, 22(32):3057. [17] 潘姿女, 丁金旺, 王克义, 等.血清人附睾蛋白4、CA125和CA19-9联合检测在子宫内膜癌诊断中的临床价值[J].中国卫生检验杂志, 2014, 24(11):1600.